As of today, RayzeBio, Inc. is officially part of Bristol Myers Squibb! We are excited to continue our mission and look forward to delivering breakthrough therapies through our differentiated radiopharmaceutical platform as part of BMS. Follow our progress Bristol Myers Squibb
RayzeBio
Biotechnology Research
San Diego, CA 17,799 followers
Targeted innovative radiopharmaceuticals for cancer
About us
RayzeBio Inc. is now part of Bristol Myers Squibb. Follow our progress delivering breakthrough therapies through our differentiated radiopharmaceutical platform @Bristol Myers Squibb or www.bms.com
- Website
-
http://www.rayzebio.com
External link for RayzeBio
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- San Diego, CA
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
San Diego, CA 92121, US
Employees at RayzeBio
Updates
-
RayzeBio reposted this
We are excited to announce our proposed acquisition by Bristol Myers Squibb. Our leading position in radiopharmaceutical therapeutics coupled with the broad and deep expertise of BMS in oncology allows us to work together to bring forth this next wave of innovation in cancer therapy for patients. https://lnkd.in/gTEy-mC4
-
We are excited to announce our proposed acquisition by Bristol Myers Squibb. Our leading position in radiopharmaceutical therapeutics coupled with the broad and deep expertise of BMS in oncology allows us to work together to bring forth this next wave of innovation in cancer therapy for patients. https://lnkd.in/gTEy-mC4
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
businesswire.com
-
Look forward to catching up in NY, London, or Miami this month at the Truist, Jefferies London, or Evercore Healthcare conference https://lnkd.in/gxaTaMTE
-
Welcome our newest board member - Tim Van Hauwermeiren, CEO of argenx!
Excited to work with our newest board member Tim Van Hauwermeiren, CEO of argenx. Tim has done an amazing job building and scaling argenx from a discovery to commercial biotech company and I look forward to his input and insights as we continue to build and scale RayzeBio as a leading radiopharmaceutical company. https://lnkd.in/gQAGzFMG
RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors
globenewswire.com
-
See you at ESMO in Madrid, Spain. On Sunday, Oct 22, we will have a poster presentation update on our ACTION-1 Phase 1b trial which is evaluating RYZ101 (Ac225 DOTATATE) in patients with refractory neuroendocrine tumors of the GI tract and pancreas. https://lnkd.in/d2Gb-vij
RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress | RayzeBio
investors.rayzebio.com
-
Thank you to our employees, board members, advisors/consultants, business partners, and investors for joining us on our journey to discover and develop innovative radiopharmaceutical therapies for patients with cancer. https://lnkd.in/gdwaPmKM
RayzeBio, Inc. Announces Closing of Upsized $358 Million Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
businesswire.com
-
Thank you to Nasdaq for hosting us for the closing bell following our IPO
RayzeBio sits at the intersection of science and innovation. 🧬 Celebrating their Nasdaq listing at the Closing Bell, $RYZB is an industry-leading pioneer in targeted radiopharmaceutical therapeutics. #NasdaqListed
-